Transplant-mediated alloimmune thrombocytopenia (TMAT) from donors with immune thrombocytopenia (ITP) can result in significant bleeding complications in the recipient. The risk to a recipient of TMAT if they receive an organ from a donor with ITP is unknown. The outcomes of recipients of organs from deceased donors with ITP recorded in the UK Transplant Registry between 2000 and 2015 were reviewed. Twenty-one deceased organ donors had a predonation diagnosis of ITP. These donors were significantly more likely to have died from intracranial hemorrhage than were all other deceased organ donors (85% vs. 57%, p < 0.001). Organs from donors with ITP resulted in 49 organ transplants (31 kidney, 14 liver, four heart), with only one case of TMAT, which occurred in a liver transplant recipient and resulted in death from bleeding complications 18 days posttransplantation. The recipient of a kidney from the same organ donor was not affected. Unadjusted 5-year patient and graft survival was significantly worse for liver transplant recipients from donors with ITP compared with liver transplant recipients from donors without ITP (64% vs. 85%, p = 0.012). Organs from donors with ITP may be considered for transplantation, but livers should be used with caution.
Introduction
The transfer of immunocompetent donor lymphocytes from transplanted organs, notably the liver, may result in the development of graft-versus-host disease (GVHD) (1) . GVHD after liver transplantation has been reported in 0.1-2% of liver transplant recipients and may progress to a fatal multisystem disease (1) (2) (3) . Donor plasma cells or B-lymphocytes transmitted with an allograft have also been reported to cause transient hemolysis when donor-specific antibodies react against recipient red cells (the passenger lymphocyte syndrome [PLS] ) (4, 5) . In addition to GVHD and PLS, there have been occasional case reports documenting the transmission of immune thrombocytopenia (ITP) from organ donors to liver transplant recipients with serious consequences (6) (7) (8) (9) (10) . In transplant-mediated alloimmune thrombocytopenia (TMAT), donor leucocytes from an organ donor with ITP produce antiplatelet antibodies that bind platelet membrane epitopes such as glycoprotein IIb/IIIa common to both donor and recipient. Only five cases of TMAT have been previously reported, all after liver transplantation. In all cases, TMAT was distinguished by severe and sudden-onset thrombocytopenia with platelets <10 9 10 9 /L within 3 days of liver transplantation (6) (7) (8) (9) (10) . While TMAT is a rare complication of liver transplantation, there has been no attempt to estimate the risk of disease transmission from organ donors with recent or past history of ITP. Consequently, there is no current guidance in the United Kingdom or the United States with regard to the safety of using organs from donors with ITP. To help inform policy on the use of organs from donors with a history of ITP, we undertook a retrospective registry analysis to establish the number of donors with ITP from which organs were used for transplantation and their associated recipient outcomes.
Methods

Identification of donors who died of ITP
The UK Transplant Registry (UKTR), a national transplant database maintained by National Health Service Blood and Transplant (NHSBT), was used to identify all organ donors with a diagnosis of ITP. The UKTR was interrogated using the search terms "ITP," "idiopathic thrombocytopaenic purpura," and "immune thrombocytopaenia" (and common misspellings and alternative combinations of these words) for all UK deceased and living organ donors between January 1, 2000, and December 31, 2015. In donors identified as having a predonation diagnosis of ITP, a search was made of their records to establish the duration of ITP, what treatments (if any) had been received, and the platelet counts at time of death. All donors with a past medical history of ITP recorded in the UKTR were included in the present analysis.
Identification of recipients from donors with ITP
The recipients of organs from donors who had ITP were identified from the UKTR, and information regarding patient and graft survival was collected. The platelet count on the third postoperative day and any subsequent history of TMAT or ITP in the transplant recipient were obtained from the recipient's transplant center. Kaplan-Meier estimates (of the survival function) were used to show death-censored graft survival and recipient survival. The univariate logrank test was used to calculate p-values. All analyses were performed using Statistical Analysis System version 9.3, and p-values <0.05 were deemed statistically significant (11) .
Statistical analysis
HLA and UK end-stage liver disease definitions
Human leukocyte antigen (HLA) mismatch level was defined according to UK allocation policy for kidneys from brain-dead donors and was based on the mismatch between donor and recipient at the HLA-A, -B, and -DR loci: level 1 was a 000 HLA-A, -B, and -DR mismatch; level 2 was a 0 HLA-DR plus 0/1 HLA-B mismatch; level 3 was a 0 HLA-DR plus 2 HLA-B mismatch or a 1 HLA-DR plus 0/1 HLA-B mismatch; and level 4 was a 2 HLA-DR or a 1 HLA-DR plus 2 HLA-B mismatch. The UKELD score was calculated based on the patient's international normalized ratio (INR), serum creatinine, serum bilirubin, and serum sodium (11) . The MELD score was calculated based on recipient serum bilirubin and creatinine levels, INR, and underlying cause of their liver disease (12, 13) .
Results
Organ donors with ITP During the 16-year study period, there were 20 440 potential deceased donors of whom 24 (0.15%) had a diagnosis of ITP at the time of organ donation. None of 11 843 living donors over this time period were known to have had ITP. Of the 24 deceased donors with history of ITP, information on whether specific treatment was given for ITP was available for 14. Of these, two of the patients with ITP died of ICH before any specific treatment was administered. Treatment in the remaining 12 patients was intravenous immunoglobulin (IVIg) and/or steroids (n = 9), splenectomy alone or splenectomy plus rituximab, eltrombopag, and romiplostim (n = 2), and IVIg plus rituximab (n = 1). Twenty-one of the 24 potential deceased donors with ITP proceeded to organ donation. Three donors with ITP did not proceed to organ donation, because of withdrawal of family consent (n = 1), positive human T-lymphotropic virus status (n = 1), and prolonged time to asystole after withdrawal of life-supporting treatment (n = 1). /L, IQR 147-267, p < 0.001) compared with donors without ITP. Four donors were diagnosed with ITP on presentation to hospital immediately before donation, and one additional donor had been diagnosed 1 week before donation. Four donors had been diagnosed within the year preceding organ donation, and the other seven donors had been diagnosed >1 year before donation, with the longest time from diagnosis to donation being 61 years. In nine cases, it was not stated in the registry or in the article notes how long before donation ITP had been diagnosed. Donors with ITP donated organs, which led to 49 organ transplants (31 kidney transplants [including three simultaneous kidney-pancreas transplants], 14 liver transplants, and four heart transplants). Survival analysis comparing renal transplant recipients from donors with and without ITP demonstrated no difference in 10-year death-censored graft survival (p = 0.672) and recipient survival (p = 0.695) ( Figure S1 ).
Clinical characteristics of donors with ITP
Clinical characteristics of kidney transplant recipients
Clinical characteristics of liver transplant recipients
The 14 liver transplant recipients from organ donors with ITP and recipients of livers from those without ITP were of similar age, sex, ethnicity, UKELD score, MELD score, and primary liver disease and had the same proportion of recipients who were listed urgently for a liver transplant (Table 1) .
Platelet counts were recorded for all liver transplant recipients on day 0 and day 3 posttransplantation, with a median platelet count on day 3 of 49 9 10 9 /L (IQR 24-76) and a median platelet count drop of 38 9 10 9 /L (IQR 17-70) from day 0 to day 3 ( Figure 1 ). The platelet count of liver transplant recipients fell in 12 (86%) of the 14 cases (Figure 1 ). These platelet counts were compared with those receiving a liver transplant within the past 3 years at Addenbrookes Hospital in Cambridge (n = 259). The median day 3 platelet count in the Cambridge cohort was 44 9 10 9 /L (IQR 30-58), and when the platelet counts dropped post liver transplantation, the median platelet count drop was 18 9 10 9 /L (IQR 10-31), which was not significantly different than the drop observed in liver recipients from organ donors with ITP (p = 0.456). None of the liver transplant recipients from Cambridge had a platelet count <10 9 10 9 /L on day 3 posttransplantation.
One of the 14 recipients of a liver from a donor with ITP (a 61-year-old man) developed TMAT posttransplantation (14) . His platelet count dropped on day 3 to 2 9 10 9 /L, and he subsequently died 18 days post liver transplantation, secondary to pulmonary hemorrhage and multiorgan failure. Platelet antibodies specific to glycoprotein Ib/XI identified in the donor were also found in the recipient after transplantation but were absent from the recipient's serum sample taken 14 days before transplantation. The donor liver time 0 biopsy sample showed marked extramedullary hematopoiesis. There was no evidence of TMAT in the recipient of a single kidney from the same donor. One liver transplant recipient developed hepatic artery thrombosis and needed urgent retransplantation, and one died secondary to hemorrhage from a ruptured vascular aneurysm (Table 1) .
Time 0 liver biopsy samples were available for two other donors with ITP. These either found no lymphocytic infiltrate or a small lymphocytic and neutrophil infiltrate; neither showed marked extramedullary hematopoiesis.
Graft and patient survival were inferior in recipients of livers from donors with ITP compared with those who received livers from all other deceased donors ( Figure 2) . None of the other early causes of death or graft failure in the liver recipients from donors with ITP were thought to be secondary to TMAT.
Heart recipients
The four recipients of hearts from organ donors with ITP were of similar age (median 43 vs. 47 years, p = 0.736), ethnicity (75% white vs. 90% white, p = 0.307), and sex (75% male vs. 62% male, p = 0.604) to all other deceased donor heart transplant recipients. The day 3 platelet counts were 143, 96, 53, and 96 9 10 9 /L, respectively. There were no reported cases of TMAT in any of the four heart transplant recipients.
Discussion
This study has described, for the first time, a national experience of using organs from donors with ITP and has established that clinically significant TMAT is uncommon in this setting. Although donors with ITP made up a very small proportion of the total donor pool (0.15%), they contributed a total of 49 organs for transplantation, and given the discrepancy between organ supply and demand, it is important that organs from donors are not rejected unnecessarily (15, 16) .
The absence of TMAT in 31 kidney and four heart transplant recipients in the present series is consistent with three previous TMAT cases after liver transplantation, in which recipients of other organs (five kidneys and one heart) from the same donors with ITP did not develop TMAT (7, 8, 10) . Passenger lymphocyte-induced hemolysis is most frequent after hematopoietic stem cell transplantation and progressively less likely after heart-lung transplantation and then after liver/small bowel/pancreas and then kidney transplantation in proportion to the number of transplanted lymphocytes (17) . A larger number of lymphocytes transmitted to the recipient in the donor graft may, therefore, explain why TMAT occurred after liver but not after kidney or heart transplantation. However, TMAT occurred in only one of 14 recipients of livers from donors with ITP and remains a relatively rare occurrence.
With only one TMAT case in this series, it is not possible to identify characteristics of donors with ITP that could distinguish those whose organs carry the greatest risk of TMAT. In this case series, and in all five previous TMAT cases, the donors all died of ICH and had a platelet count of <20 9 10 9 /L before death (Table 2) . Of the five ITP donors with a reported clinical history, three had been refractory to multiple therapies including splenectomy, but two died as a result of ICH as part of their acute ITP presentation. Failure of the donor with ITP to respond to splenectomy suggests that their liver is a major site of platelet destruction by the reticuloendothelial system (18) (19) (20) . In our series, one recipient of a liver from a donor with ITP who had required splenectomy developed TMAT and one did not. Extramedullary hematopoiesis in the donor liver represents a greater burden of transplanted hematopoietic tissue. There were a limited number of time 0 liver biopsies available. One other liver transplant biopsy showed focal lymphocytic and neutrophilic infiltrate but no extramedullary hematopoiesis. The degree of extramedullary hematopoiesis and its significance in predicting TMAT could be explored in future studies.
The progressive fall in platelet count from day 0 to day 3 in liver recipients was expected. The platelet count is usually reduced post orthotopic liver transplantation, typically falling to a nadir around postoperative day 4, followed by a gradual recovery (21, 22) . This fall in platelet count is thought to be caused by factors such as reduced thrombopoietin production, hemodilution, and platelet sequestration in the reperfused liver graft. There may also be patient specific variables such as sepsis, bleeding or disseminated intravascular coagulation (increased platelet consumption), medication, viral infection, or heparininduced thrombocytopenia (22) . Thus, other causes of thrombocytopenia must be considered in cases of suspected TMAT. Further, like ITP, TMAT remains a clinical diagnosis. Serological testing may be supportive if the same antiplatelet antibodies are found in the recipient and the donor. However, the significance of these antibodies is unclear since it is unknown whether these can be detected in liver recipients of donors with ITP unaffected by TMAT. Second, platelet-associated IgG can be elevated in nonimmune thrombocytopenia, and antibodies to specific platelet glycoproteins cannot always be detected in patients with ITP (23). Therefore, negative serological testing of the donor and the recipient does not exclude the presence of TMAT.
The natural history and optimal treatment of TMAT are unclear. In three previously reported cases, the platelet counts had improved within 1-3 weeks with only IVIg with or without steroids (7, 8, 10) . In two reported cases refractory to multiple therapies including splenectomy, the platelets recovered after liver retransplantation day 11 for rejection in one case or after retransplantation day 43 for refractory TMAT in the other (6,9). The kidney transplant recipient in the present study who developed ITP 8 years posttransplantation is not likely to have TMAT, because lymphocytes do not persist in the long term after solid organ transplantation (4). The incidence of ITP is approximately 4 per 100 000 personyears but occurs more frequently with the background of immune dysregulation (24, 25) . In a series of 256 liver transplant recipients, eight (0.7%) cases of new ITP occurred at a median of time from transplant of 53.5 months (range 1.9-173) (26) .
The risk of TMAT in recipients of livers from donors with ITP is small. It is possible that a number of recipient and donor characteristics affect the likelihood of TMAT, but the pathogenesis is poorly understood. Hence, although the risk is present, organs from these donors should not be discarded unnecessarily. Clinicians and recipients should be made aware of the risk of TMAT.
There are some limitations to this study. The retrospective nature of the registry analysis may limit the accuracy and completeness of the donor and recipient data. A diagnosis of ITP would have to have been known by the patient's medical team for the diagnosis to be recorded in the past medical history of the donor. Thus, it is possible that the numbers presented in this study are an underestimate of the actual number of donors who had ITP. We also cannot exclude the possibility of milder episodes of TMAT that were not recognized as such by the treating teams. A further limitation with this study is the small number of donors identified with ITP. Interpretation of the overall effect on recipient outcome can be difficult.
Conclusions
Although the exact mechanism of TMAT is not fully understood, there is no evidence from the UK experience of using kidneys, pancreases, and hearts from donors with ITP to suggest it is unsafe. However, there is a small risk of TMAT after liver transplantation, and we have demonstrated inferior recipient survival after liver transplantation from donors with ITP. Transplant teams will have to consider the severity of liver disease and health of a potential recipient when balancing the risk of accepting the liver of a donor with ITP against the risk of further delay in transplantation.
